about
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaAdoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma modelSerum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patientsCytotoxic T lymphocyte responses against melanocytes and melanoma.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Immunomodulatory cytokines as therapeutic agents for melanomaSneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma.Cancer vaccines inducing antibody production: more pros than cons.Tremelimumab: a review of development to date in solid tumors.Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.Immunotherapy of melanoma: present options and future promises.Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies.Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.Introducing MARCo: Histoserological Findings of a Multi-Organic Paraneoplastic Syndrome in Cutaneous Melanoma Patients.Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.Vitiligo treatment demystified: a flowchart for stratified treatment approaches.Q56898607Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic ReviewMetastatic pulmonary melanoma complicated with erythroderma and recurrent sepsis
P2860
Q26785746-D19EF538-944E-449A-8E60-05005766C311Q26824310-DA4A745A-B7A1-4DDC-B50A-15131E98CB50Q34409836-E8D7295A-F777-4C48-921A-12CAA97D6BA3Q34618599-548231CE-B02E-45DC-AF6E-C4ECA68BA488Q35172610-96C79E19-A4F2-4C68-A721-D1E03294418BQ36547213-80AD04A3-473C-4393-9E24-67353B7BA6D2Q37014061-5A28D4E2-4ABA-43CB-B984-D1153A10E199Q37070203-5B09CF6A-13D1-433C-981D-8AF4565CA16AQ37158935-05F41234-C5F5-49D8-B536-A4640240C208Q37932519-C9F18FB9-4921-4BED-975E-F90E9F6D78D5Q38085028-470A583F-5573-433E-AB0E-0DC12E1120F9Q38241987-0B7F33DB-0F75-46CC-B619-288A1A75643EQ38318683-E6392666-639F-4D96-B3F7-22F13387B46BQ38673109-EE7AFB24-EDE3-4C3A-83E1-E8275C435CDBQ39300005-315651CE-75BD-445E-8597-A506048A91F1Q40256338-E713D05E-C936-4205-A261-07BF07B429B7Q40713858-BE176E5F-8D59-4E01-9979-16D373F5D0A7Q42364290-AA4B66D2-D83A-4186-A0FE-254758EE254BQ47287952-94120ACD-A8B1-4959-8FC3-6F0651A744E8Q48077141-45E19A34-13DE-435A-95C7-74B206773D10Q56898607-EA24A73D-AE0B-4449-956F-44E3DA80500CQ58585047-7828D23E-050C-40C8-A36F-DECE803D5BA8Q58754203-C0B2A957-DE7A-4E1C-A2A4-1C2D2CB052C5
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Autoimmunity and treatment outcome in melanoma.
@ast
Autoimmunity and treatment outcome in melanoma.
@en
type
label
Autoimmunity and treatment outcome in melanoma.
@ast
Autoimmunity and treatment outcome in melanoma.
@en
prefLabel
Autoimmunity and treatment outcome in melanoma.
@ast
Autoimmunity and treatment outcome in melanoma.
@en
P2093
P1476
Autoimmunity and treatment outcome in melanoma.
@en
P2093
Alexander Mm Eggermont
Marna G Bouwhuis
Stefan Suciu
Timo L M Ten Hagen
P304
P356
10.1097/CCO.0B013E328341EDFF
P577
2011-03-01T00:00:00Z